Search Patents
  • In-vitro fertilization systems with spermatozoa separated into X-chromosome and Y-chromosome bearing populations
    Patent number: 8137967
    Abstract: An IVF system for successfully utilizing spermatozoa separated into X-chromosome bearing and into Y-chromosome bearing population for insemination. The IVF system includes fertilization medium that can shorten the time from insemination to cleavage and a portable incubator for the transportation of maturing oocytes and inseminated oocytes comprising a straw (19) and an incubation element (20) that can be sealed with a cap (22).
    Type: Grant
    Filed: August 21, 2006
    Date of Patent: March 20, 2012
    Assignee: XY, LLC
    Inventors: George E. Seidel, Kehuan Lu, Tae Kwang Suh
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7129339
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: October 31, 2006
    Assignee: sanofi pasteur limited
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression
    Publication number: 20110065123
    Abstract: Cell-based methods for rapid real time assay of a presence of Clostridium difficile toxin and/or cells are provided, using an assay having a toxin-enhancing antibody and a sensitive cell line carrying FcyR receptors, and kits for this assay. An ultrasensitive cell based immunocytotoxicity assay for detecting less then 1 pg/ml of C. difficile toxins in clinical samples. A TcdA-specific monoclonal antibody, AIH3, was found to significantly enhance the cytotoxicity of TcdA to macrophages and monocytes. The AIH3-dependent enhancement of glucosyltransferase activity, cytoskeleton disruption, and TNF-a production induced by TcdA was demonstrated also in RAW 264.7 cells. Methods for high level recombinant expression of C. difficile toxins in Bacillus cells, and vectors for expression, strains of Bacillus carrying the vectors are provided.
    Type: Application
    Filed: May 15, 2009
    Publication date: March 17, 2011
    Inventors: Hanping Feng, Saul Tzipori, Guilin Yang
  • LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
    Publication number: 20030108538
    Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.
    Type: Application
    Filed: April 23, 2002
    Publication date: June 12, 2003
    Inventors: Michael C. Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South
  • Human amine receptor
    Patent number: 5928890
    Abstract: A Human amine receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also provided are methods for detecting compounds which bind to and activate and bind to and inhibit such polypeptide and the use of compounds for treating diseases related to the under-expression and over-expression of the Human amine receptor of the present invention. Also disclosed are methods for detecting mutations in the nucleic acid sequence encoding the polypeptide and for detecting altered levels of the soluble form of the polypeptide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 27, 1999
    Assignee: Human Genome Sciences, Inc.
    Inventor: Yi Li
  • Melusin a muscle specific protein, as a drug target for prevention and treatment of heart failure
    Patent number: 7531714
    Abstract: The present invention concerns non-human transgenic animals as model study for human pathologies, being transgenic for having altered melusin expression. The non-human transgenic animals are to be used as models to study heart pathologies and provide therapies thereof, wherein the heart pathologies are heart failure, and in particular diluted cardiomyopathy.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: May 12, 2009
    Assignee: Universita' Degli Studi de Torino
    Inventors: Mara Brancaccio, Lorenzo Silengo, Fiorella Altruda, Giuseppe Lembo, Luigi Fratta, Guido Tarone
  • Codon optimised recombinant allergens
    Patent number: 7173117
    Abstract: The present invention relates to codon optimised polynucleotides which are efficiently expressed in mammalian cells and encode insect proteins from Dermaphagoids dust mite. In particular, the optimised codon polynucleotides encode a protein from Dermaphagoides pteronyssinus, such as DerP1 or proDerP1. The present invention also provides methods of preparing pharmaceutical compositions comprising the expression of the codon optimised polynucleotides, and vectors and transformed host cells comprising them.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: February 6, 2007
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Alex Bollen, Paul Jacobs, Alain Jacquet, Marc Georges Francis Massaer
  • FGF-CX polynucleotide sequences and methods of producing same
    Patent number: 7291483
    Abstract: The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-GX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: November 6, 2007
    Assignee: CuraGen Corporation
    Inventors: Richard A. Shimkets, Sudhirdas K. Prayaga
  • Methods of identifying adipocyte specific genes, the genes identified, and their uses
    Publication number: 20110288034
    Abstract: Disclosed is a method of identifying genes that are over-expressed in adipose tissue as compared to pre-adipocyte tissue or other tissues comprising performing differential gene expression analysis between the white adipose tissue (WAT) or stromal vascular tissue (SVT) from any two different mice selected from the group consisting of wild-type, HMGI-C?/?, ob/ob, and HMGI-C?/? ob/ob genotype mice. Based on this method a number of nucleotide sequences are identified whose expression is adipocyte specific. The identified nucleotide sequences and their corresponding polypeptides are then used to prevent adipogenesis, to treat diabetes, and to screen for small-molecules that can modulate or prevent adipogenesis and to treat diabetes.
    Type: Application
    Filed: November 23, 2010
    Publication date: November 24, 2011
    Inventors: Kiran K. Chada, Roland Chouinard, Hena Ashar, Abu Sayed
  • Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
    Patent number: 7727534
    Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: June 1, 2010
    Assignee: Oncolytics Biotech Inc.
    Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
  • Tumor suppressor gene
    Patent number: 5910442
    Abstract: The present invention relates to a novel tumor suppressor gene, SSeCKSS. It is based, at least in part, on the discovery of a gene, hitherto referred to as "322" (Lin et al., 1995, Mol. Cell. Biol. 15:2754-2762) but now referred to as SSeCKS, which was found to be down-regulated in certain transformed cells. Further, the SSeCKS gene product was subsequently shown to be a substrate of protein kinase C. SSeCKS protein has been shown to act as a mitogenic regulator and as an inhibitor of the transformed phenotype.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: June 8, 1999
    Assignee: Mount Sinai School Of Medicine
    Inventor: Irwin H. Gelman
  • Blood cell sorting methods and systems
    Patent number: 8753888
    Abstract: The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: June 17, 2014
    Assignee: The General Hospital Corporation
    Inventors: Denise L. Faustman, Douglas E. Burger
  • Glutamate transporters
    Patent number: 6818391
    Abstract: This invention pertains to the identification of a novel class of glutamate transporters. In particular, this invention pertains to the discovery that proteins originally considered to perform an entirely different function (BNPI, DNPI, etc.), in fact, transport glutamate into synaptic vesicles. Designated VGLUT glutamate transporters, the transporters provide good targets with which to screen for modulators of glutamate uptake into synaptic vesicles.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: November 16, 2004
    Assignee: The Regents of the University of California
    Inventors: Robert H. Edwards, Elizabeth E. Bellocchio, Robert T. Fremeau, Jr., Richard J. Reimer
  • Gene encoding melanocortin-5 receptor and methods of use
    Patent number: 5710265
    Abstract: Genes encoding melanocortin receptors have been identified, isolated, cloned and localized to their chromosomal positions. These genes have been used to transfect mammalian cells lacking endogenous melanocortin receptors to induce expression. Additionally, melanocortin receptor binding, secondary signalling, and tissue distribution has been characterized. The genes and their gene products may therefore be used to to provide therapeutic vehicles for the treatment of processes involving the function of melanocortin receptors.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: January 20, 1998
    Assignee: The Regents Of The University Of Michigan
    Inventors: Tadataka Yamada, Ira Gantz
  • Isolation and sequencing of the hazel FAD2-Ngene
    Patent number: 6025172
    Abstract: The invention relates to the isolation from hazel (Corylus avellana L.) of the FAD2-N gene coding for the .DELTA.12 desaturase enzyme of the microsomal fraction and, in particular, provides the nucleotide sequence and the deduced amino-acid sequence of the gene and provides for the use of the FAD2-N gene as a probe for the isolation of other plant desaturases. The invention also relates to the use of the FAD2-N gene for altering desaturase levels and consequently the fatty-acid composition of the plant.
    Type: Grant
    Filed: March 4, 1997
    Date of Patent: February 15, 2000
    Assignee: Soremartec S.A.
    Inventors: Maria Dani, Sergio Catello
  • Antisense oligonucleotide modulation of raf gene expression
    Patent number: 6806258
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating or preventing conditions, including hyperproliferative conditions, associated with raf expression.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: October 19, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Brett P. Monia
  • Methods of controlling proliferation and differentiation of stem and progenitor cells
    Patent number: 7312078
    Abstract: A method of ex-vivo expanding a population of stem cells, while at the same time inhibiting differentiation of the stem cells. The method comprises ex-vivo providing the stem cells with conditions for cell proliferation and with at least one copper chelator in an amount and for a time period for permitting the stem cells to proliferate and, at the same time, for reducing a capacity of the stem cells to differentiate.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: December 25, 2007
    Assignees: Gamida Cell Ltd., Hadasit Medical Research Services and Development, Ltd.
    Inventors: Tony Peled, Eitan Fibach, Avi Treves
  • Bioengineered Tissue Constructs and Methods for Production and Use
    Publication number: 20110293666
    Abstract: Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components, e.g., without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be treated in various ways such that the cells of the bioengineered constructs can be devitalized and/or removed without compromising the structural integrity of the constructs. Moreover, the bioengineered constructs of the invention can be used in conjunction with biocompatible/bioremodelable solutions that allow for various geometric configurations of the constructs.
    Type: Application
    Filed: January 14, 2011
    Publication date: December 1, 2011
    Inventors: Xianyan Wang, Katherine C. Faria
  • RAGE protein derivatives
    Patent number: 7470521
    Abstract: The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids encoding the fusion proteins, as well as vectors and cells comprising such nucleic acids.
    Type: Grant
    Filed: July 20, 2005
    Date of Patent: December 30, 2008
    Assignee: Critical Therapeutics, Inc.
    Inventors: Theresa O'Keefe, Peter Luciano, Shixin Qin
  • Method for Obtaining Sterile Human Amniotic Fluid and Uses Thereof
    Publication number: 20140336600
    Abstract: Provided herein is a pre-Caesarean method for collecting amniotic fluid from a patient. A needle is inserted into the incision site for the future C-section, which may be under ultrasound guidance, through which the amniotic fluid is drawn under a low level suction and, optionally, gravity to a sterile collection container. The method encompasses filtering and/or irradiating the amniotic fluid to collect biomolecules of interest such as growth factors and/or stem cells.
    Type: Application
    Filed: May 12, 2014
    Publication date: November 13, 2014
    Inventor: Carl Randall Harrell